Geomatics in injury prevention: the science, the potential and the limitations.

BACKGROUND: Geomatics describes the activities involved in acquiring and managing geographical data and producing geographical information for scientific, administrative and technical endeavors. As an emerging science, geomatics has a great potential to support public health. Geomatics provides a conceptual foundation for the development of geographic information systems (GIS), computerized tools that manage and display geographical data for analytical applications. As descriptive epidemiology typically involves the examination of person, place and time in the occurrence of disease or injury, geomatics and GIS can play an important role in understanding and preventing injury. AIM: This article provides a background to geomatics for those in the injury prevention field who are unfamiliar with spatial analysis. We hope to stimulate researchers and practitioners to begin to use geomatics to assist in the prevention of injury. METHODS: The authors illustrate the potential benefits and limitations of geomatics in injury prevention in a non-technical way through the use of maps and analysis. RESULTS: By analysing the location of patients treated for fall injuries in Central Toronto using GIS, some demographic and land use variables, such as household income, age, and the location of homeless shelters, were identified as explanatory factors for the spatial distribution. CONCLUSION: By supporting novel approaches to injury prevention, geomatics has a great potential for efforts to combat the burden of injury. Despite some limitations, those with an interest in injury prevention could benefit from this science.

A new mixed micellar preparation for oral vitamin K prophylaxis: randomised controlled comparison with an intramuscular formulation in breast fed infants.

OBJECTIVE: To compare a new oral preparation of vitamin K1 (Konakion MM) containing lecithin and glycocholic acid with a standard intramuscular (IM) preparation during the first 8 weeks of life in exclusively breast fed infants. METHODS: Infants were randomised at birth to the IM group (1 mg vitamin K) or the oral group (2 mg given at birth and repeated at 7 and 30 days of life). Prothrombin time (INR), plasma vitamin K1, and PIVKA II (undercarboxylated prothrombin) were monitored at 14, 30, and 56 days of age. RESULTS: Seventy nine infants were randomised to the oral group and 77 to the IM group. Sixty seven infants in each group completed eight weeks of the study. Prothrombin times did not differ between the two groups. Mean (SD) plasma vitamin K1 values (in ng/ml) decreased in both groups over time, but were higher in the oral group at 14 and 56 days: 2.0 (1.6) v 1.3 (1.1) at 14 days; 0.5 (0.3) v 0.5 (0.7) at 30 days; and 0.5 (0.8) v 0.2 (0.2) at 56 days of life. PIVKA II was raised (> or = 0.1 AU/ml) in cord blood in 47% of the infants. By 14 days, only one infant in each group had a raised PIVKA II value and both of these initially had high concentrations of PIVKA II in cord blood. At 30 days, there were no raised PIVKA II values. At 56 days, there were no raised PIVKA II values in the oral group, although three infants in the IM group had raised values. CONCLUSIONS: Plasma vitamin K concentrations were at least equal or significantly higher in babies given oral vitamin K supplements compared with IM treated babies at the time points measured. Through the first 8 weeks of life, multiple doses of the new oral preparation maintain haemostasis and vitamin K status in breast fed infants at least equal to that of the intramuscular preparation.

Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements.

OBJECTIVE: To increase the phylloquinone (vitamin K1) concentration of human milk with maternal oral phylloquinone supplements such that both the phylloquinone intake of breastfed infants and their serum concentrations of phylloquinone would approach those of formula-fed infants who are known to be at much less risk for hemorrhagic disease of the newborn. DESIGN: Two stages: stage I, longitudinal, randomized study of 6 weeks' duration; and stage II, longitudinal, randomized, double-blind, placebo-controlled study of 12 weeks' duration. SETTING: Patients from a private pediatric practice in Madison, WI. PATIENTS: Stage I: sequential sampling of 20 lactating mothers to determine the level of maternal supplementation needed in stage II. Ten mothers received 2.5 mg/d oral phylloquinone, and 10 mothers received 5.0 mg/d oral phylloquinone. Stage II: sequential sampling of 22 human milk-fed infants and lactating mothers. All infants received 1 mg of phylloquinone at birth. Eleven mothers received a placebo; 11 mothers received 5 mg/d phylloquinone. MEASUREMENTS AND RESULTS: In stage I, both 2.5 and 5.0 mg/d phylloquinone significantly increased the phylloquinone content of human milk at both 2 and 6 weeks. As expected, 5.0 mg had a greater effect (mean +/- SD, 58.96 +/- 25.39 vs 27.12 +/- 12.18 ng/mL at 2 weeks). In stage II, the vitamin K-supplemented group had significantly higher maternal serum phylloquinone concentrations, higher phylloquinone milk concentrations, and higher infant plasma phylloquinone concentrations at 2, 6, and 12 weeks compared with the placebo group. At 12 weeks infant phylloquinone intakes were significantly higher for the vitamin K group than the placebo group (9.37 +/- 4.55 vs 0.15 +/- 0.07 microgram/kg per day). This corresponded to a plasma phylloquinone concentration in the vitamin K group of 2.84 +/- 3.09 vs 0.34 +/- 0.57 ng/mL in the placebo group. At 12 weeks, the prothrombin times did not differ between the groups, but the des-gamma-carboxy-prothrombin (partially carboxylated prothrombin thought to be a measure of vitamin K deficiency) was significantly elevated in the placebo group compared with the vitamin K group (1.48 +/- 1.19 vs 0.42 +/- 0.55 ng/mL). CONCLUSION: In exclusively breastfed infants who receive intramuscular phylloquinone at birth, the vitamin K status as measured by plasma phylloquinone and des-gamma-carboxy-prothrombin concentrations is improved by maternal oral supplements of 5 mg/d phylloquinone through the first 12 weeks of life.

Liquid feed passage route into stomach compartments, influence of abomasal infusions on plasma glucose, and supplementation of dry rations with liquid feeds from lick-wheel feeders.

Passage route into stomach compartments of liquid feeds containing a marker was studied by feeding a liquid supplement and molasses from a lick-wheel feeder and by infusing the liquid supplement into the reticulorumen 30 min prior to sampling contents of the reticulorumen and abomasum and 4 h prior to sampling blood for plasma glucose. Recovery from reticulorumen and concentration of marker in abomasal ingesta gave no evidence of rumen bypass, this supported by a gross correlation of .92 between rumen ammonia nitrogen and nonprotein nitrogen intake from liquid feeds. Plasma glucose values were not different. Preinfusion and postinfusion plasma glucose values were similar for abomasal infusion of about 454 g of molasses, 20% crude protein liquid supplement, and for the basal diet. Values were lower for abomasal infusion of the 35% crude protein liquid supplement (Pro-Lix) than for the 20% crude protein liquid supplement. When complete rations containing 11.5, 13.0, and 14.5% crude protein were supplemented with either molasses or a 20% crude protein liquid supplement fed from lick-wheel feeders, intake averaged .53 and .34 kg per animal daily for the respective liquid feeds. There was no effect on milk yield, solids-corrected milk, milk fat content, protein content, solids-not-fat percent, or body weight change. There was an interaction of protein level and liquid feeds in which plasma glucose was increased by liquid feeds in higher but not in lower protein diets.